Maravai LifeSciences Sees Unusually Large Options Volume (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) saw some unusual options trading activity on Wednesday. Stock traders bought 1,002 put options on the stock. This is an increase of approximately 1,791% compared to the typical daily volume of 53 put options.

Wall Street Analyst Weigh In

Several research firms have weighed in on MRVI. Wells Fargo & Company boosted their price target on shares of Maravai LifeSciences from $4.00 to $4.50 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Wall Street Zen raised Maravai LifeSciences from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $5.38.

Maravai LifeSciences Stock Performance

NASDAQ:MRVI opened at $2.87 on Thursday. The firm has a market cap of $737.79 million, a PE ratio of -3.19 and a beta of 0.43. Maravai LifeSciences has a fifty-two week low of $1.66 and a fifty-two week high of $4.11. The company has a debt-to-equity ratio of 0.85, a quick ratio of 5.69 and a current ratio of 6.60. The business has a 50 day moving average price of $3.26 and a 200-day moving average price of $3.33.

Maravai LifeSciences (NASDAQ:MRVI) last issued its earnings results on Wednesday, February 25th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03. Maravai LifeSciences had a negative net margin of 70.40% and a negative return on equity of 22.79%. The company had revenue of $49.87 million for the quarter, compared to the consensus estimate of $49.06 million. Equities research analysts predict that Maravai LifeSciences will post -0.24 earnings per share for the current year.

Hedge Funds Weigh In On Maravai LifeSciences

A number of hedge funds have recently modified their holdings of MRVI. Sprott Inc. purchased a new stake in shares of Maravai LifeSciences during the third quarter worth about $29,000. Virtu Financial LLC purchased a new position in Maravai LifeSciences during the 4th quarter valued at about $34,000. Insigneo Advisory Services LLC purchased a new position in Maravai LifeSciences during the 4th quarter valued at about $34,000. Quantessence Capital LLC bought a new position in Maravai LifeSciences during the 3rd quarter valued at approximately $31,000. Finally, Stifel Financial Corp bought a new position in Maravai LifeSciences during the 4th quarter valued at approximately $36,000. Hedge funds and other institutional investors own 50.25% of the company’s stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.